Show simple item record

dc.contributor.authorPhillips, Elizabeth H
dc.contributor.authorIype, Rohan
dc.contributor.authorWirth, A.
dc.date.accessioned2021-09-30T11:55:58Z
dc.date.available2021-09-30T11:55:58Z
dc.date.issued2021en
dc.identifier.citationPhillips EH, Iype R, Wirth A. PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. BJR. 2021 Sep 14;20210576.en
dc.identifier.pmid34520242en
dc.identifier.doi10.1259/bjr.20210576en
dc.identifier.urihttp://hdl.handle.net/10541/624574
dc.description.abstractFDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1259/bjr.20210576en
dc.titlePET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphomaen
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Sciences, University of Manchester, Manchester, UKen
dc.identifier.journalBritish Journal of Radiologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record